Retrospective analysis of thalassemia patients in secondary care hospital: Ras Al Khaimah, United Arab Emirates

Letter to Editor


Department of Internal Medicine, RAK Medical and Health Sciences University, RAK, UAE



Thalassemia, a genetic disorder, results in the production of abnormal hemoglobin (Hb). A mature Hb molecule is an oligomer composed of four subunits (monomers) two alpha-globin (α-globin) and two beta-globin (β-globin) polypeptides attached to a heme prosthetic group.[1] In alpha-thalassemia (α-thalassemia), there is a decrease in the making of α-globin chains, and this results in a reduced red cell (erythrocyte) Hb level. In beta-thalassemia (β-thalassemia), there is a decline in the production of β-globin chains leading to unpaired α-globin chains as a by-product, which, being unstable erythroid precursors, precipitate and result in injury to the membrane as well as the unfolding of the protein response leading to toxicity and death of the cells.[1] In Thalassemia major, the child inherits two defective globin genes (one each from a parent), while in Thalassemia minor, only one defective globin gene is inherited (from only one parent). Ineffective erythropoiesis is responsible for the typical symptoms of thalassemia. Classical symptoms of Thalassemia major include pallor, poor development, and abdominal enlargement in children and infants. Radiological evidence in these children and young adults includes thinning of the long bones with a “sun-ray appearance” and “dilation of the marrow cavities”. The skull also develops a “hair-on-end” appearance due to an increase in the width in the diploic space. Some patients also have enlarged maxillary sinuses along with a tendency to have a maxillary overbite.[2]

Shivappa P, Bernhardt GV, Mufti MM, Banu A. A review on epidemiology and thalassemia distribution, in relevance to United Arab Emirates population. OnLine J Biol Sci 2021;21:280-4.  Back to cited text no. 1
Marengo-Rowe AJ. The thalassemias, and related disorders. Proc (Bayl Univ Med Cent) 2007;20:27-31.  Back to cited text no. 2
Willcox M, Björkman A, Brohult J. Falciparum malaria and β-thalassaemia trait in Northern Liberia. Ann Trop Med Parasitol 1983;77:335-47.  Back to cited text no. 3
De Sanctis V. β-thalassemia distribution in the old world: A historical standpoint of an ancient disease. Mediterr J Hematol Infect Dis 2017;9 e2017018.  Back to cited text no. 4
El-Kalla S, Baysal E. α-Thalassemia in the United Arab Emirates. Acta Haematol 1998;100:49-53.  Back to cited text no. 5
Baysal E. α-Thalassemia syndromes in the United Arab Emirates. Hemoglobin 2011;35:574-80.  Back to cited text no. 6
Walker EM, Jr, Walker SM. Effects of iron overload on the immune system. Ann Clin Lab Sci 2000;30:354-65.  Back to cited text no. 7
Calzada D, Baos S, Cremades-Jimeno L, Cárdaba B. Immunological mechanisms in allergic diseases and allergen tolerance: The role of treg cells. J Immunol Res 2018;2018:6012053.  Back to cited text no. 8
Guidelines for the Management of Transfusion Dependent Thalassaemia. 3rd ed. TIF. 2014. Retrieved June 14, 2021. Available from:  Back to cited text no. 9
Triggiani M, Patella V, Staiano RI, Granata F, Marone G. Allergy and the cardiovascular system. Clin Expe Immunol 2008;153 (Suppl 1):7-11.  Back to cited text no. 10
Masoud MS, Alokail MS, Yakout SM, Khattak M, Al Rehaili MM, Wani K, et al. Vitamin D supplementation modestly reduces serum iron indices of healthy Arab adolescents. Nutrients 2018;10:1870.  Back to cited text no. 11